Alnylam’s drug, vutrisiran, was approved for patients with transthyretin amyloid cardiomyopathy, or ATTR-CM, to reduce ...

Heart disease patients now have another treatment option. The U.S. Food and Drug Administration has approved Alnylam ...

Amvuttra’s clearance in a rare form of cardiomyopathy could help Alnylam turn a regular profit — if it can wrest control of a ...

In this deep dive, BioSpace explores the diverse therapeutic modalities now in development, as well as the opportunities and ...

New research suggests that drugs like Ozempic may provide more health benefits than previously thought. These medications, ...

The tool is said to predict “off-target” effects for seven drugs that could aid in cellular hypertrophy prevention.

University of Virginia School of Medicine scientists have created a computational tool to accelerate the development of new ...

In a new study in the peer-reviewed journal Diabetes Technology & Therapeutics (DTT), investigators evaluated biomarkers for ...